Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use

Abstract

The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-yl-methyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula I, which may be used for example for tumour therapy.

1. A crystalline form of the monomethanesulfonic acid addition salt of a compound of formula I, 
       
         
           
           
               
               
           
         
         having non-needle-shaped crystals. 
       
     
     
       2. A crystalline form according to  claim 1  of the methanesulfonic acid addition salt of a compound of formula I, which comprises at least 95% by weight crystals of the β-modification. 
     
     
       3. A crystalline form according to  claim 1  of the methanesulfonic acid addition salt of a compound of formula I, which shows on X-ray diffraction a peak at an angle of refraction 2theta of 20°, said peak having a relative line intensity of about 65% as compared to the most intense line in the diagram. 
     
     
       4. A pharmaceutical composition, comprising the crystal form according to  claim 1  of the methanesulfonic acid addition salt of a compound of formula I and a pharmaceutically acceptable carrier.